A Systematic Review of HER2 Blockade for the Curative Treatment of Gastroesophageal Adenocarcinoma: Successes Achieved and Opportunities Ahead

Over one million cancer related deaths are attributable to esophageal and gastric cancer worldwide annually, ranking third and sixth as most frequent causes of global cancer mortality. [1] Neoadjuvant chemoradiotherapy (nCRT) is commonly used for the treatment of patients with esophageal adenocarcinoma (EAC), while perioperative chemotherapy is often administered to patients with gastric cancer. [1,2] Notwithstanding the benefit gained with multimodality treatment in both cancer types, the prognosis remains dismal with a high distant relapse rate following surgery.[1] Optimization of treatment is thus urgently needed.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research